Floatz logo

Deferitazole

Transfusional Hemosiderosis

ShireSmall moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Transfusional Hemosiderosis cohort.

Asset / SponsorPhaseRating
Deferasirox
Shire
Phase 4A
DESFERRIOXAMINE B
Ain Shams University
Phase 4BBB
Deferiprone
Ain Shams University
Phase 4BB
DESFERRIOXAMINE B
Ain Shams University
Phase 2/3BB
Deferasirox
Novartis Pharmaceuticals
Phase 2B
DESFERRIOXAMINE B
Novartis Pharmaceuticals
Phase 2B
Ferriprox
Ain Shams University
Phase 2/3B

Same molecule, other indications

Deferitazole is also rated in:

iron poisoningDormant
B
Indicative ·
59 / 100
View asset →
beta thalassemiaDormant
B
Indicative ·
58 / 100
View asset →
iron metabolism diseaseDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →